 Evaluation of unfavourable outcome-related factors in patients affected by renal cell cancer in treatment with everolimus and previously treated with a Vascular endothelial growth factor VEGF inhibitor i.e. sunitinib, sorafenib,pazopanib, or bevacizumabinterferon 